Safety and effectiveness of fixed dose combination of amitriptyline and chlordiazepoxide (Libotryp® and Libotryp-DS®) in the management of depression with co-morbid anxiety: protocol and design of a prospective, single arm, multi-centric, PMS study

Sunil Kumar Y. Yadav, Snehal Muchhala, Seema Bhagat, Rahul Rathod, Amey Mane, Bhavesh Kotak

Abstract

Background: Depression and anxiety are most disabling psychiatric conditions and add significantly to global health-related burden. Lifetime prevalence of major depression and anxiety disorders are very common and many times they can co-exist in the same time frame. The outcomes are poorer in such situations and compliance to medication is key to improve prognosis. A combination of tricyclic antidepressants and benzodiazepine is more practical in terms of compliance, and advantageous than that of a single class of drugs for the management of depression with co-morbid anxiety. This study will evaluate the safety and effectiveness of a fixed dose combination of amitriptyline and chlordiazepoxide as a part of post marketing surveillance.

Methods: This is a prospective, single-arm, multi-centre, study which enrols patients who have been initiated with FDC of amitriptyline and chlordiazepoxide (Libotryp®: amitriptyline 12.5 mg and chlordiazepoxide 5 mg or libotryp-DS®: amitriptyline 25 mg and chlordiazepoxide 10 mg) tablets for the treatment of depression with co-morbid anxiety. A total of 375 patients will be enrolled and clinical assessments for safety will be done at follow up visits; assessments for effectiveness will be done using Hamilton Depression Rating Scale (HDRS or HAM-D) and Hamilton Anxiety Rating Scale (HARS or HAM-A).

Conclusions: This study will provide more evidence on safety and usefulness of FDC of amitriptyline and chlordiazepoxide for the treatment of depression with co-morbid anxiety from Indian context.

Trial registration: Trial registration number is CTRI/2021/03/031971.

Keywords

Depression, Anxiety, Fixed dose combination, Amitriptyline, Chlordiazepoxide

Full Text:

PDF

References

Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-22.

Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of dsm-iv disorders in the national comorbidity survey replication. Arch General Psychiat. 2005;62:593-602.

Sagar R, Dandona R, Gururaj G, Dhaliwal RS, Singh A, Ferrari A, et al. The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990–2017. Lancet Psychiat. 2020;7:148-61.

Jacobson N, Newman M. Anxiety and depression as bidirectional risk factors for one another: a meta-analysis of longitudinal studies. Psychol Bull. 2017;143:1155-200.

Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiat Sci. 2015;24:210-26.

Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34:1299-308.

Sahoo S, Khess CRJ. Prevalence of depression, anxiety, and stress among young male adults in India: a dimensional and categorical diagnoses-based study. J Nerv Mental Dis. 2010;198:901-4.

Zhou Y, Cao Z, Yang M, Xi X, Guo Y, Fang M, et al. Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder. Sci Rep. 2017;7:40511.

Jaeschke R, Siwek M, Dudek D. The impact of anxiety disorders on the quality of compliance among patients with co-morbid psychiatric or medical conditions: There are many questions but where can we find the answers? Arch Psychiat Psychother. 2011;13:15-20.

Zhao Y, Bijlsma EY, Verdouw PM, Garssen J, Groenink L. The contribution of contextual fear in the anxiolytic effect of chlordiazepoxide in the fear-potentiated startle test. Behav Brain Res. 2018;353:57-61.

DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Internal Med. 2000;160:2101-7.

Farooq S, Singh SP. Fixed dose-combination products in psychiatry: Systematic review and meta-analysis. J Psychopharmacol. 2014;29:556-64.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Therap. 2001;23:1296-310.

LimbitroL® (chlordiazepoxide) (amitriptyline HCI) DS (double strength) Tablets Tablets Tranquilizer-Antidepressant Suicidality and Antidepressant Drugs. Available at: https://www.accessdata.fda.gov/dru. Accessed on 20 November 2022.

Smith M. Clinical Response to amitriptyline and chlordiazepoxide-amitriptyline (limbitrol®) in anxiety-depressive states: a double-blind study. Psychosomat. 1973;14:168-75.

Feighner JP, Brauzer B, Gelenberg AJ, Gomez E, Kiev A, Kurland ML, et al. A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. Psychopharmacol. 1979;61:217-25.

Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0. 2017. Available at: https://www.meddra.org/. Accessed on 20 November 2022.

The use of the WHO-UMC system for standardised case causality assessment. Available at: https://www.who.int/medicines/areas/quality_safety/safety_ pdf. Accessed on 20 November 2022.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat. 1960;23:56-62.

Hamilton M. The assessment of anxiety states by rating. BR J Med Psychol. 1959;32:50-5.

Comparison of chlordiazepoxide-amitriptyline combination with amitriptyline alone in anxiety depressive states. PsycNET. Available at: https://psyc net.apa.org/record/1972-23202-001. Accessed on 20 November 2022.

Sharp R. The Hamilton rating scale for depression. Occup Med. 2015;65:340.

Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton depression rating scale: has the gold standard become a lead weight?. Am J Psychiat. 2004; 161:2163-77.

Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med. 2015;65:601.

Maier W, Buller R, Philipp M, Heuser I. The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14:61-8.

Houck J. Combined therapy in anxiety-depressive syndromes. II. Comparative effects of amitriptyline and limbitrol (chlordiazepoxide-amitriptyline). Dis Nervous Sys. 1970;31:421-6.

Houck JE. Combined therapy in anxiety-depressive syndromes. I. Comparative effects of limbitrol (chlordiazepoxide-amitriptyline) and placebo. Dis Nervous Sys. 1970;31:269-73.